Lakefront Biotherapeutics (GLPGF) Free Cash Flow Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Free Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | -3.13% |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | 16.01% |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | -1.95% |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | -20.15% |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | 21.16% |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | 80.69% |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | -0.65% |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 0.18% |
| Dec 31, 2025 | 52.00% |
| Mar 31, 2025 | 15.89% |
| Dec 31, 2024 | 51.79% |
| Jun 30, 2024 | 26.86% |
| Mar 31, 2024 | 1.75% |
| Dec 31, 2023 | 3.16% |
| Mar 31, 2023 | -10.10% |
| Dec 31, 2022 | -64.62% |
| Mar 31, 2022 | 9.18% |
| Dec 31, 2021 | -50.55% |
| Jun 30, 2021 | -12.99% |
| Mar 31, 2021 | -42.05% |
| Dec 31, 2020 | -40.10% |
| Jun 30, 2020 | 85.99% |
| Mar 31, 2020 | -46.11% |
| Dec 31, 2019 | -190.36% |
| Jun 30, 2019 | -50.55% |
| Mar 31, 2019 | -31.69% |
| Dec 31, 2018 | -8.23% |